SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells - ScienceDirect
Glimmers of Hope—New Strategies for Overcoming Treatment Resistance in Patients with BRAF V600E-mutated Metastatic Colorectal Cancer - touchONCOLOGY
BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer
Emerging treatment options for BRAF-mutant colorectal cancer | GICTT
BRAF Biomarker | Colorectal Cancer Alliance
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer
![BRAF V600E [VE1] - Biocare Medical](https://biocare.net/wp-content/uploads/3248.jpg "BRAF V600E [VE1] - Biocare Medical")
BRAF V600E [VE1] - Biocare Medical
Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI
Cancers | Free Full-Text | The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations
Targeting BRAF V600E in metastatic colorectal cancer: where are we today? - ecancer
BRAF Mutation and Its Importance in Colorectal Cancer | IntechOpen
Frontiers | Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
Heparanase modulates the prognosis and development of BRAF V600E-mutant colorectal cancer by regulating AKT/p27Kip1/Cyclin E2 pathway | Oncogenesis
Prise en charge du patient avec cancer colo-rectal métastatique (CCRm) BRAF muté – FMC-HGE
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer | NEJM
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines - ScienceDirect
Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI
Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology | JCO Precision Oncology
How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer | Cancer Cell International | Full Text
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR‐Deficient Colorectal Cancer - Sahin - 2021 - The Oncologist - Wiley Online Library
Art of using maintenance therapy in a patient with metastatic colon cancer harboring RAS-wt/BRAF V600E | Biomedical Research and Therapy
Cancers | Free Full-Text | BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
